Resultados da pesquisa - Portal para modelos de dados médicos (portal MDM)

Filtrar os resultados da pesquisa
Selecionar modelos de dados

Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

5 Resultados da pesquisa.

Neurological Examination Week 38 Mepolizumab HES NCT00086658 - Neurological Examination Week 38

- 15/07/2017 - 1 Formulário, 1 Grupo de itens, 18 Elementos de dados, 1 Idioma

Grupo de itens: Neurological Examination

Study part: Neurological Examination Week 38/ Early Withdrawal visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Neurological Examination Week 16 Mepolizumab HES NCT00086658 - Neurological Examination Week 16

- 12/07/2017 - 1 Formulário, 1 Grupo de itens, 18 Elementos de dados, 1 Idioma

Grupo de itens: Neurological Examination

Study part: Neurological Examination Week 16. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Neurological Examination Week 8 Mepolizumab HES NCT00086658 - Neurological Examination Week 8

- 09/07/2017 - 1 Formulário, 1 Grupo de itens, 18 Elementos de dados, 1 Idioma

Grupo de itens: Neurological Examination

Study part: Neurological Examination Week 8. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Neurological Examination Week 4 Mepolizumab HES NCT00086658 - Neurological Examination Week 4

- 11/06/2017 - 1 Formulário, 1 Grupo de itens, 18 Elementos de dados, 1 Idioma

Grupo de itens: Neurological Examination

Study part: Neurological Examination Week 4. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Neurological Examination Day 1 Pre-Infusion Mepolizumab HES NCT00086658 - Neurological Examination Day 1 Pre-Infusion

- 11/06/2017 - 1 Formulário, 1 Grupo de itens, 18 Elementos de dados, 1 Idioma

Grupo de itens: Neurological Examination

Study part: Neurological Examination Day 1 Pre-Infusion.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.